Literature DB >> 2474312

The effect of different vigabatrin treatment regimens on CSF biochemistry and seizure control in epileptic patients.

E Ben-Menachem1, L I Persson, P J Schechter, K D Haegele, N Huebert, J Hardenberg, L Dahlgren, J P Mumford.   

Abstract

1. Vigabatrin, 50 mg kg-1, was administered orally as add-on therapy to 11 patients with drug-resistant complex partial epilepsy as a single dose, then once every third day for 2 months, every other day for 2 months and daily for 1 month. 2. Lumbar punctures were carried out prior to treatment and at the end of each dosage regimen and cerebrospinal fluid (CSF) evaluated for concentrations of free and total GABA, homocarnosine (GABA-histidine dipeptide), homovanillic acid (HVA), 5-hydroxyindole acetic acid (5-HIAA) and vigabatrin. 3. Each regimen resulted in significant increases in CSF concentrations of free and total GABA and homocarnosine compared with the immediately preceding regimen. 4. CSF concentrations of HVA significantly increased after a single vigabatrin dose but returned to pre-treatment levels with subsequent dosing schedules. In contrast, 5-HIAA concentrations also increased with the single dose but were significantly decreased, compared with pre-treatment values, following alternate day and daily vigabatrin administration. 5. Seizure frequency progressively decreased with decreasing dosing interval. Daily vigabatrin administration was associated with greater than 50% decrease in seizures in 8 of the 10 patients treated.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2474312      PMCID: PMC1379684          DOI: 10.1111/j.1365-2125.1989.tb03466.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  17 in total

1.  Epilepsy.

Authors:  L Spero
Journal:  Lancet       Date:  1982-12-11       Impact factor: 79.321

2.  Cerebrospinal fluid GABA as an index of brain GABA activity.

Authors:  J Grove; M G Palfreyman; P J Schechter
Journal:  Clin Neuropharmacol       Date:  1983       Impact factor: 1.592

3.  Gamma-aminobutyric acid and the search for new anticonvulsant drugs.

Authors:  B S Meldrum
Journal:  Lancet       Date:  1978-08-05       Impact factor: 79.321

4.  Audiogenic seizure protection by elevated brain GABA concentration in mice: effects of gamma-acetylenic gaba and gamma-vinyl GABA, two irreversible GABA-T inhibitors.

Authors:  P J Schechter; Y Tranier; M J Jung; P Böhlen
Journal:  Eur J Pharmacol       Date:  1977-10-15       Impact factor: 4.432

5.  gamma-Vinyl GABA (4-amino-hex-5-enoic acid), a new selective irreversible inhibitor of GABA-T: effects on brain GABA metabolism in mice.

Authors:  M J Jung; B Lippert; B W Metcalf; P Böhlen; P J Schechter
Journal:  J Neurochem       Date:  1977-11       Impact factor: 5.372

6.  Gamma-vinyl-GABA: a single-blind trial in patients with epilepsy.

Authors:  L Gram; B B Lyon; M Dam
Journal:  Acta Neurol Scand       Date:  1983-07       Impact factor: 3.209

7.  Double-blind study of vigabatrin in the treatment of drug-resistant epilepsy.

Authors:  C A Tassinari; R Michelucci; G Ambrosetto; F Salvi
Journal:  Arch Neurol       Date:  1987-09

8.  Concentration gradients of free and total gamma-aminobutyric acid and homocarnosine in human CSF: comparison of suboccipital and lumbar sampling.

Authors:  J Grove; P J Schechter; N F Hanke; Y de Smet; Y Agid; G Tell; J Koch-Weser
Journal:  J Neurochem       Date:  1982-12       Impact factor: 5.372

9.  Effects of single doses of vigabatrin on CSF concentrations of GABA, homocarnosine, homovanillic acid and 5-hydroxyindoleacetic acid in patients with complex partial epilepsy.

Authors:  E B Menachem; L I Persson; P J Schechter; K D Haegele; N Huebert; J Hardenberg; L Dahlgren; J P Mumford
Journal:  Epilepsy Res       Date:  1988 Mar-Apr       Impact factor: 3.045

10.  Increased gamma-aminobutyric acid (GABA), homocarnosine and beta-alanine in cerebrospinal fluid of patients treated with gamma-vinyl GABA (4-amino-hex-5-enoic acid).

Authors:  J Grove; P J Schechter; G Tell; J Koch-Weser; A Sjoerdsma; J M Warter; C Marescaux; L Rumbach
Journal:  Life Sci       Date:  1981-05-21       Impact factor: 5.037

View more
  16 in total

Review 1.  Clinical relevance of measuring GABA concentrations in cerebrospinal fluid.

Authors:  P J Schechter; A Sjoerdsma
Journal:  Neurochem Res       Date:  1990-04       Impact factor: 3.996

2.  Vigabatrin's complicated journey--to be or not to be?

Authors:  Elinor Ben-Menachem
Journal:  Epilepsy Curr       Date:  2009 Sep-Oct       Impact factor: 7.500

Review 3.  Measuring human brain GABA in vivo: effects of GABA-transaminase inhibition with vigabatrin.

Authors:  O A Petroff; D L Rothman
Journal:  Mol Neurobiol       Date:  1998-02       Impact factor: 5.590

4.  Sub-chronic low dose gamma-vinyl GABA (vigabatrin) inhibits cocaine-induced increases in nucleus accumbens dopamine.

Authors:  Wynne K Schiffer; Douglas Marsteller; Stephen L Dewey
Journal:  Psychopharmacology (Berl)       Date:  2003-04-09       Impact factor: 4.530

5.  Electroretinogram changes in a pediatric population with epilepsy: is vigabatrin acting alone?

Authors:  Bláthnaid McCoy; Thomas Wright; Shelly Weiss; Cristina Go; Carol A Westall
Journal:  J Child Neurol       Date:  2011-02-22       Impact factor: 1.987

Review 6.  Vigabatrin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in epilepsy and disorders of motor control.

Authors:  S M Grant; R C Heel
Journal:  Drugs       Date:  1991-06       Impact factor: 9.546

Review 7.  A risk-benefit assessment of vigabatrin in the treatment of neurological disorders.

Authors:  J Srinivasan; A Richens
Journal:  Drug Saf       Date:  1994-05       Impact factor: 5.606

8.  Effect of vigabatrin on striatal dopamine receptors: evidence in humans for interactions of GABA and dopamine systems.

Authors:  H A Ring; M R Trimble; D C Costa; M S George; P Verhoeff; P J Ell
Journal:  J Neurol Neurosurg Psychiatry       Date:  1992-09       Impact factor: 10.154

Review 9.  Vigabatrin. Clinical pharmacokinetics.

Authors:  E Rey; G Pons; G Olive
Journal:  Clin Pharmacokinet       Date:  1992-10       Impact factor: 6.447

10.  Single-blind, placebo-controlled multicenter trial of vigabatrin in the treatment of epilepsy. The Italian Study Group on Vigabatrin.

Authors: 
Journal:  Ital J Neurol Sci       Date:  1992-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.